IGM-6268 / Atreca, BeOne Medicines, IGM Biosciences - LARVOL DELTA

Evaluation of IGM-6268 in Healthy Adults and Patients With Mild to Moderate COVID-19 (clinicaltrials.gov) - P1 | N=26 | Terminated | Sponsor: IGM Biosciences, Inc. | N=102 ➔ 26 | Trial completion date: Dec 2022 ➔ Jul 2022 | Recruiting ➔ Terminated | Trial primary completion date: Nov 2022 ➔ May 2022; Sponsor Decision

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Infectious Disease • Novel Coronavirus Disease

Evaluation of IGM-6268 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=54 | Terminated | Sponsor: IGM Biosciences, Inc. | Trial completion date: Apr 2022 ➔ Aug 2022 | Recruiting ➔ Terminated; Sponsor decision

Trial completion date • Trial termination

Evaluation of IGM-6268 in Healthy Adults and Patients With Mild to Moderate COVID-19 (clinicaltrials.gov) - P1 | N=102 | Recruiting | Sponsor: IGM Biosciences, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Novel Coronavirus Disease

Evaluation of IGM-6268 in Healthy Adults and Patients With Mild to Moderate COVID-19 (clinicaltrials.gov) - P1; N=102; Not yet recruiting; Sponsor: IGM Biosciences, Inc.

Clinical • New P1 trial • Infectious Disease • Novel Coronavirus Disease

Evaluation of IGM-6268 in Healthy Volunteers (clinicaltrials.gov) - P1; N=48; Recruiting; Sponsor: IGM Biosciences, Inc.

Clinical • New P1 trial

IGM Biosciences Announces Expansion of IgM Platform into Infectious Diseases, Publication of Preclinical Data in Nature Demonstrating Engineered IgM Antibody Antiviral Activity for the Treatment and Prevention of COVID-19 (GlobeNewswire) - "IGM Biosciences, Inc....announced the expansion of its IgM antibody platform into infectious diseases, with the anticipated advancement of a new pipeline candidate, IGM-6268, into the clinic in the third quarter of 2021....The announcement coincides with the publication in Nature of an article...The article describes results from preclinical studies demonstrating significantly greater neutralization of SARS-CoV-2 with an IgM antibody compared to IgG antibodies, the potent neutralization of all evaluated mutant Variants of Concern (VoC) and Variants of Interest (VoI), and the ability to provide effective preventative and therapeutic protection when delivered intranasally in mice."

New trial • Preclinical • Infectious Disease • Novel Coronavirus Disease

[VIRTUAL] The Anti-Tumor Activity of Igm-8444, an Agonistic Death Receptor 5 (DR5) IgM Antibody, Is Sensitized in Combination with Chemotherapy and Bcl-2 Inhibitors in NHL and AML (ASH 2020) - "Combinations with chemotherapy including cytarabine and doxorubicin or targeted agents such as Bcl-2 inhibitor ABT-199 resulted in synergistic in vitro cytotoxicity in multiple cell lines, as determined by Bliss synergy scores. Conclusions : These data support the clinical development of IGM-8444 in hematological malignancies as a single agent, in combination with standard of care chemotherapy, and in combination with targeted agents that impact the intrinsic signaling pathway such as Bcl-2 inhibitor ABT-199. Initiation of a Phase I clinical study evaluating the safety of IGM-8444 is anticipated in 2020."

Combination therapy • IO Biomarker • Hematological Malignancies • Hepatology • Solid Tumor • TNFA

[VIRTUAL] IGM Antibodies with Very Potent Agonism to DR-5 Induced Apoptosis and as Anti-Tumor Agents (PEGS 2020) - "Primate models show very low to no evidence of toxicity. We are scaling these antibodies for IND enabling studies and FIH human trials."

Hematological Malignancies • Oncology

IGM Biosciences Announces First Quarter 2020 Financial Results and Provides Corporate Update (GlobeNewswire, IGM Biosciences) - "Collaboration with Atreca and BeiGene for COVID-19: IGM, Atreca, Inc., and BeiGene, Ltd. announced plans to collaborate to help address the COVID-19 pandemic. The companies will leverage their combined technology and expertise in an effort to discover, develop, and manufacture novel IgM and IgA antibodies targeting SARS-CoV-2 for the potential treatment of COVID-19. If research, manufacturing, and regulatory activities proceed very well, then the companies believe that an antibody may be ready to begin clinical testing in the first half of 2021."

Licensing / partnership • Infectious Disease • Novel Coronavirus Disease